论文部分内容阅读
目的探讨五酯胶囊联合复方益肝灵胶囊在治疗非酒精性脂肪肝患者的肝功能保护作用,评价其对患者肝脏功能、血脂、肝脏影像及中医症候的影响,为临床治疗非酒精性脂肪肝提供依据。方法随机选取2012年8月—2014年6月间岱山县第一人民医院肝病门诊收治的诊断为非酒精性脂肪肝患者68例作为研究对象,将患者按照随机分配的原则分为观察组和对照组。观察组患者采用五酯胶囊联合复方益肝灵胶囊治疗,对照组患者单纯给予复方益肝灵胶囊治疗,30 d为一疗程,2个疗程后对2组患者治疗后临床疗效、肝脏B超、总胆固醇(TC)、甘油三酯(TG)、谷氨酰转肽酶(GGT)、谷草转氨酶(AST)及血清谷丙转氨酶(ALT)进行分析。结果经过2个疗程治疗后观察组患者治愈占29.4%(10/34),显效占47.1%(16/34),有效占17.6%(6/34),总有效率为94.1%,显著优于对照组(χ2=9.13,P=0.028);治疗前后2组患者血清ALT、AST、GGT、TG、TC改善值,观察组患者要显著高于对照组(t=3.99,t=5.29,t=4.10,t=2.88,t=3.79,P<0.05);2组患者治疗后肝脏B超变化组间差异无统计学意义(χ2=2.83,P>0.05)。结论对非酒精性脂肪肝患者采用五脂胶囊联合复方益肝灵胶囊进行治疗,能够显著改善患者的肝脏功能及血脂,临床疗效显著,值得推广应用。
Objective To investigate the protective effect of Wuyi capsule combined with Yiganling Capsule in the treatment of non-alcoholic fatty liver disease in patients with liver function, evaluate its effects on liver function, blood lipids, liver imaging and TCM symptoms, for the clinical treatment of non-alcoholic fatty liver Provide evidence. Methods Sixty-eight patients with non-alcoholic fatty liver were randomly selected from the First Affiliated Hospital of Daishan County from August 2012 to June 2014. The patients were randomly divided into observation group and control group group. Patients in the observation group were treated with Wushen Capsule combined with Yiganling Capsule. Patients in the control group were treated with Compound Yiganling Capsule alone for 30 days. After two courses of treatment, the clinical efficacy, B-ultrasound, Total cholesterol, TG, GGT, AST and ALT were analyzed. Results After 2 courses of treatment, the cure rate of observation group was 29.4% (10/34), the effective rate was 47.1% (16/34), the effective rate was 17.6% (6/34), the total effective rate was 94.1%, which was significantly better than (Χ2 = 9.13, P = 0.028). Before and after treatment, serum ALT, AST, GGT, TG and TC in two groups were significantly higher than those in the control group (t = 3.99, t = 5.29, t = 4.10, t = 2.88, t = 3.79, P <0.05). There was no significant difference between the two groups in the changes of liver ultrasonography after treatment (χ2 = 2.83, P> 0.05). Conclusion The treatment of non-alcoholic fatty liver patients with Wuzhi Capsule combined with Yiganling Capsule can significantly improve liver function and blood lipid in patients with significant clinical effect, which is worth popularizing and applying.